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High-dose therapy (HDT) with autologous hematopoietic cell
rescue (AHCR) improves survival in patients with multiple mye-
loma, but is not curative due to a continuous risk of relapse.
One approach to try to reduce relapse is to optimize pretransplant
therapy and the preparative regimen. We investigated the out-
come of sequential HDT with AHCR. Patients were initially
treated with standard dose chemotherapy (primarily VAD) to
maximum response. They then received cyclophosphamide 4
gm/m2 followed by G-CSF and peripheral blood hematopoietic
cell collection by apheresis upon count recovery. They were
then treated with etoposide 2 gm/m2 followed by G-CSF and
apheresis upon count recovery. The transplant preparative regi-
men consisted of carmustine 500 mg/m2 on day -4 and melphalan
200 mg/m2 on day -2 followed by AHCR on day 0. Seventy-six
patients were treated between 1997 and 2001. The patient popu-
lation included 56% males with a median age at transplant of 54
years (range 39-68 years). Forty patients had IgG myeloma, 11 pa-
tients had IgA myeloma, 8 patients had light chain only disease, 5
patients had nonsecretory disease, 1 patient had IgM myeloma and
subtype is unknown in 11 patients. Forty patients were trans-
planted with CD34 selected cells. The Kaplan-Meir estimated me-
dian progression-free survival is 4.2 years (CI 3.1-6.0 years) with
a median overall survival of 7.2 years (CI 4.8-11.4 years). The me-
dian follow up of the 36 surviving patients is 8.46 years with
a range of 4.71 to 11.4 years. One patient was lost to follow up.
The Kaplan-Meir estimated progression-free survival at 10 years
is 35% with overall survival of 45%. Two patients died of inter-
stitial pneumonitis at 21 and 76 days post transplant and two pa-
tients died of secondary leukemia at 694 and 712 days post
transplant. High dose sequential chemotherapy is well tolerated
and results in long term survival in a significant proportion of pa-
tients with multiple myeloma.118
RETROSPECTIVE COMPARISON OF SECONDARY MOBILIZATION STRATE-
GIES IN CANDIDATES FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANTION WITH A FOCUS ON RESOURCE UTILIZATION:
PLERIXAFOR + G-CSF VERSUS OTHER REGIMENS
Perkins, J., Bookout, R., Sapiro, J., Alsina, M., Ayala, E., Field, T.L.,
Kharfan-Dabaja, M.A., Perez, L.E., Ochoa-Bayona, J.L.,
Tomblyn, M., Daily, K., Elstner, C., Anasetti, C., Fernandez, H.F. Mof-
fitt Cancer Center, Tampa, FL
Successful autologous transplantation relies on hematopoietic cell
mobilization that allows adequate CD34+ cell collection. Depite ap-
propriate mobilization approaches, a significant number of patients
(pts) do not mobilize adequate CD34+ cells and require a second
round of mobilization therapy. We performed a retrospective analy-
sis of our experience with different secondary mobilization strategies
with a focus on resource utilization. Primary endpoint was compar-ing plerixafor versus other regimens with respect to the rate of suc-
cessful second mobilization defined as the ability to collect at least
2106 CD34+ cells/kg (cumulative). Included here are 96 pts receiv-
ing their primary mobilization therapy between 2000-09. Pts are di-
vided into two groups depending on the secondary mobilization
therapy given: Plerixafor + G-CSF (PG; n5 38) or Other (OTH;
n5 58). which included chemotherapy +G-CSF in 15 pts, G-CSF
alone in 23 pts or G-CSF andGM-CSF in 20 pts. There were no dif-
ferences in pt characteristics between the two groups except for
a higher number of non-Hodgkin’s lymphoma pts in the PG group
and more pts with multiple myeloma in the OTH group. In the
PG mobilized group, 29% were first mobilized with chemothera-
py +G-CSF and 71% were mobilized with G-CSF alone. In the
OTH pts, 41% received chemotherapy +G-CSF, 43% G-CSF
alone, and 16% G-CSF +GM-CSF. Median numbers of CD34+
cells (x 106/kg) collected after the first mobilization were 0.39 (0-
1.76) in the PG pts and 0.56 (0-2.08) in the OTH pts. Pts in the
PG group received a median of 2 doses of plerixafor (range 1-4) dur-
ing their second mobilization regimen. Eight of the 38 PG pts were
enrolled on clinical trials requiring at least 2 doses of plerixafor and
a minimum of 2 aphereses. Outcomes following the second mobili-
zation and resource utilization from the first day of second
mobilization to the last day of pheresis are shown below. Thirty-
two of the 38 PG pts (84%) were able to collect a total of at least 2
 106 CD34+ cells/kg from both mobilizations to proceed to trans-
plant; this is compared to 47/58 (80%) in theOTHgroup (p5 0.62).
Of those pts that were transplanted, there were no differences in time
to neutrophil or platelet recovery. The current data suggest that
when using plerixafor plus G-CSF in this setting there is a potential
for significant cost savings based on the reduced apheresis and hos-
pitalization requirements when compared to other forms of mobili-
zation.119
QUALITY OF UMBILICAL CORD BLOODUNITS STORED FOR AUTOLOGOUS
USE AND INFUSED INTRAVENOUSLY IN CHILDREN WITH ACQUIRED
NEUROLOGICAL CONDITIONS
Sun, J., Allison, J., McLaughlin, C., Sledge, L., Waters-Pick, B.,
Kurtzberg, J. Duke University, Durham, NC
Background: Numerous animal models demonstrate neurological
and survival benefits of bone marrow or umbilical cord blood (CB)
infusion in the setting of stroke, thermal injury, ischemia, intracra-
nial hemorrhage and spinal cord injury. Based on these data, we ini-
tiated a pilot study to determine the safety and feasibility of
intravenous (IV) administration of autologous CB (aCB) in young
children with acquired neurological disorders. Most units were elec-
tively stored in private CB banks at the request and expense of the
